Symbiotec Pharmalab shares set to list; grey market signals ~19% premium

Listing Day Arrives for Symbiotec Pharmalab

Symbiotec Pharmalab's shares are scheduled to make their market debut on Tuesday, 1 September, with trading on both the BSE and NSE from 10 AM, as reported by CNBC TV18 and Livemint. A BSE notice dated 31 August confirmed that the equity shares will be listed and admitted to dealings in the 'B' group of securities, according to Livemint.

The initial public offering (IPO) of the Madhya Pradesh-based pharmaceutical and biotechnology company was open for subscription from 24 August to 27 August, with a price band of ₹933 to ₹988 per share. The issue comprised a fresh issue of ₹150 crore and an offer for sale (OFS) of shares worth up to ₹1,607 crore by existing shareholders, as reported by CNBC TV18. Promoter Satwani Holdings, along with investors Rosewood Investments and India Business Excellence Fund - III, participated in the OFS.

Grey Market Signals and Analyst Predictions

As of Tuesday morning, the grey market premium (GMP) for Symbiotec Pharmalab shares stood at ₹185, indicating an estimated listing price of around ₹1,173 per share — approximately 18.72% higher than the IPO price of ₹988, according to both CNBC TV18 and Livemint. CNBC TV18 noted that grey market premiums are only an indicator of investor sentiment in the unofficial market and can change rapidly, and are not a reliable indicator of the actual listing price.

Livemint reported that over the past 14 sessions, the GMP fluctuated between ₹185 and ₹410, according to analysts. Mahesh M. Ojha, Vice President, Research and Business Development at Kantilal Chhaganlal Securities, predicted a 20–22% premium over the issue price on listing. Ojha suggested that allottees may consider booking partial profits on listing while retaining the balance for the long term to participate in the company's growth potential.

Ojha underscored that the company operates four manufacturing facilities across Rau, Pithampur, Ujjain and Mhow, with more than 2,500 employees and 156 R&D scientists. He noted that the company has strong backward integration, diversified product offerings, global regulatory approvals, and expanding capacity, which provide a solid platform for long-term growth. At nearly 58 times post-IPO FY26 P/E, Ojha said the valuation appears reasonable compared with listed peers.

IPO Details and Company Profile

CNBC TV18 reported that the ₹1,757-crore IPO was subscribed 71.26 times at the close of the bidding process. At the upper end of the price band, Symbiotec is expected to command a post-issue market capitalisation of ₹6,348.5 crore. Of the fresh issue proceeds, ₹112.5 crore will be used for partial repayment of debt, while the remaining amount will be utilised for general corporate purposes. Proceeds from the OFS will accrue to the selling shareholders.

Symbiotec operates two API manufacturing facilities with a combined capacity of 584.67 metric tonnes for chemical synthesis and 300 kilolitres for fermentation, as reported by CNBC TV18. The company's manufacturing operations have received approvals from the US FDA, EU-GMP, and Japan's PMDA. The company claims a 44.2% global market share in steroidal API and a 26.9% share in corticosteroid API, according to CNBC TV18.

For FY25, Symbiotec reported a net profit of ₹96.8 crore on revenue of ₹751.6 crore, and for the quarter ended June 2025, a net profit of ₹40 crore on revenue of ₹220 crore, as reported by CNBC TV18. The company's promoter holding is 26.91%, with an InvAscent advised fund holding a 37.19% stake and Motilal Oswal Private Equity holding a 44.2% stake, according to CNBC TV18. Listed peers include Divi's Laboratories, Cohance Lifesciences, and Laurus Labs.

Raghavender Satyanarayana, Chairman and Managing Director of Symbiotec Pharmalab, said the company has completed most of the capital expenditure and expects the new businesses to grow as large as its core steroid API business, as reported by CNBC TV18.

As the market opens, the actual listing price will determine whether the grey market's optimistic signal translates into a strong debut, though analysts caution that such premiums are not always reliable indicators.